期刊文献+

慢性肾衰竭血液透析患者血浆溶血磷脂酸检测及其临床意义 被引量:3

下载PDF
导出
摘要 目的:观察慢性肾衰竭(CRF)血液透析患者血浆溶血磷脂酸(LPA)水平,并探讨LPA水平在CRF血液透析患者的意义。方法:检测20例CRF血液透析患者血浆LPA浓度,并测定血清总胆固醇(TC),三酰甘油(TG),高密度脂蛋白胆固醇(HDL-C),低密度脂蛋白胆固醇(LDL-C)及尿素氮(BUN),血肌酐(Scr)。结果:CRF血液透析患者血浆LPA水平(4.656±1.793)μmol/L与健康对照组(2.199±0.583)μmol/L相比,差异具有统计学意义(P<0.01)。血浆LPA的水平与高胆固醇血症、高三酰甘油血症、低的高密度脂蛋白血症、高的低密度脂蛋白血症无相关性。结论:(1)CRF血液透析患者血浆LPA水平明显高于健康对照组。(2)CRF血液透析患者血浆LPA水平与血脂的水平无相关性。(3)LPA可作为CRF血液透析患者动脉粥样硬化的预警指标之一。
出处 《中国中西医结合肾病杂志》 2010年第1期55-57,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 吉林省科技厅基金资助项目(No.200505206)
  • 相关文献

参考文献18

  • 1Ritz E.Wanner C.Lipid changes and statins in chronic renal insufficiency.J Am Soc Nephrol,2006,7(12 Suppl 3):S226-S230.
  • 2Ristic V,Tepsic V,Ristic-Medié D,et al.Plasma and erythrocyte phospholipid fatty acids composition in Serbian hemodialyzed patients.Ren Fail,2006,28(3):211-216.
  • 3Gustin C,Delaive E,Dieu M,et al.Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure.Arterioscler Thromb Vasc Biol,2008,28(3):491-497.
  • 4Siess W,Tigyi G.Thrombogenic and atherogenic activities of lysophosphatidic acid.J Cell Biochem,2004,92(6):1086-1094.
  • 5张耀全,冯兵,李芙蓉,杨旭,周剑锋,袁发焕.兔慢性肾衰竭加速性动脉粥样硬化病理形态学变化[J].中国中西医结合肾病杂志,2008,9(6):498-501. 被引量:4
  • 6Aoki J.Mechanisms of lysophosphatidic acid production.Semin Cell Dev Biol,2004,15(5):477-489.
  • 7蒋文功,肖笑,梁彪.慢性肾衰患者血清磷脂酶A_2活性的变化及意义[J].广州医学院学报,2001,29(2):82-82. 被引量:2
  • 8Siess W,Zangl KJ,Essler M,et al.Lysophosphatidic acid mediates the rapid activation of plateletsand endothelial cells by mildly oxidized low densitylipopmtein and accumulates in human atherosclerotic lesiona.Proc Natl Acad Sci U S A,1999,96(12):6931-6936.
  • 9Navab M,Berliner JA,Subbanagounder G,et al.HDL and the inflammatory response induced bv LDL-derived oxidized phospholipids Arterioscler Thromb Vase Biol,2001,21(4):481-488.
  • 10Sano T,Baker D,Virag T,et al.Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood.J Biol Chem,2002,277(24):21197-21206.

二级参考文献25

  • 1侯凡凡,马志刚,梅长林,戎殳,黄颂敏,刘先蓉,袁伟杰,郭云珊,王莉,何强,王秀玲,桑晓红,栗霄立.中国五省市自治区慢性肾脏病患者心血管疾病的患病率调查[J].中华医学杂志,2005,85(7):458-463. 被引量:183
  • 2陈思锋,吴中立.体液和组织磷脂酶A_2简便快速测定法[J].第二军医大学学报,1989,10(3):254-256. 被引量:210
  • 3齐向明,吴永贵,吴国仲,林辉,钱浩,郝丽.依那普利联合霉酚酸酯对大鼠糖尿病肾脏协同保护作用及机制[J].中华肾脏病杂志,2005,21(9):538-542. 被引量:9
  • 4杨旭,冯兵,叶自林,袁发焕,杨惠标,牟娇.MG-132对慢性肾衰大鼠治疗作用的初步研究[J].重庆医学,2007,36(10):935-937. 被引量:9
  • 5赵水平主编.临床血脂学:第一版[M].湖南科学技术出版社,1999.132-134.
  • 6[1]Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A, 1999, 96: 6931-6936.
  • 7[2]Gueguen G, Gaige B, Grevy JM, et al. Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation. Biochemistry, 1999, 38: 8440-8450.
  • 8[4]Sonoda H, Aoki J, Hiramatsu T, et al. A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J Biol Chem, 2002, 277: 34254-34263.
  • 9[5]Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta, 1989,1001: 282-285.
  • 10[6]Gouni-Berthold I, Sachinidis A. Possible non-classic intracellular and molecular mechanisms of LDL cholesterol action contributing to the development and progression of atherosclerosis. Curr Vasc Pharmacol, 2004, 2: 363-370.

共引文献7

同被引文献27

  • 1丁少波,陈树明,郑东文,刘思明,陈祥洪,黄洪英,欧阳英.慢性肾衰竭患者血浆总同型半胱氨酸与心、脑血管并发症的关系[J].中南药学,2004,2(4):211-214. 被引量:4
  • 2韦立新,唐庆贺,孙璐,石怀银,郭爱桃,游联璧.人体冠状动脉粥样硬化斑块中氧化低密度脂蛋白和新生血管与斑块稳定性的关系[J].中华病理学杂志,2006,35(3):138-141. 被引量:37
  • 3Kalantar-Zadeh K, Fouque D, Kopple JD. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients [ J ]. J Ren Nutr, 2004, 14 (2) :64-71.
  • 4Caw A, Murray HM, Brown EA, et al. Plasma lipoprotein (a) [ Lp(a) ] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER) [J ]. Atherosclerosis, 2005,180 (2) : 381-388.
  • 5Pennell P, Leclercq B, Delahunty MI, et al. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease [ J ]. Clin Nephrol, 2006, 66 (5) :336-547.
  • 6Edelstein C, Shapiro SD, Klezovitch O, et al. Macrophage metalloelastase, MMp-12 cleaves human apolipoprotein (a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein (a) biology[J]. J Biol Chem, 1999, 274(15) :10019-10023.
  • 7Diaz-Peromingo JA, Carbajal DG, Alban-Salgado A. Lipoprotein (a) in patients on hemodialysis[ J]. Acta Med Austriaca, 2004, 31(3):73-75.
  • 8Schumacher M, Kessler A, Bahlemann G, et al. Acute changes in concentrations of apolipoproteins A- I , B, C- II and lipoprotein (a) in serum covering the period from directly before to 48 hours after chronic haemodialysis [ J ]. Eur J Clin Chem Clin Biochem, 1994,32(3) : 123-125.
  • 9Dati F,Tate JR,Marcovina SM,et al. First WHO/IFCC international reference reagent for lipoprotein (a) for immunoassay-Lp ( a ) SRM 2B [ J ]. Clin Chem Lab Med,2004,42 (6) :670-676.
  • 10Shah SV,Baliga R,Rajapurkar M. Oxidants in chronic kidney disease[J].{H}Journal of the American Society of Nephrology,2007,(1):16-28.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部